HologicNearest Resistance: $20 Nearest Support: $17.50 Catalyst: Earnings, Gen-Probe Purchase Last up today, medical diagnostics firm Hologic ( HOLX) is down double-digits on the week following the one-two punch of an earnings miss and an acquisition that the firm is paying a premium for. While announcing a revenue shortfall yesterday morning, the firm announced that it was buying Gen-Probe ( GPRO) at a 20% premium to the firm's value last week. Mr. Market isn't reacting well to that combination. From a technical standpoint, the news broke HOLX down below previous support at $20, a price level that had held shares up since the start of February. With this stock unable to catch a bid at previous levels and the next nearest support level still a dollar and change away, it makes sense for bargain hunters to turn their sights elsewhere right now. To see these stocks in action, check out the at Most-Searched Stocks portfolio on Stockpickr. -- Written by Jonas Elmerraji in Baltimore.
Twitter and become a fan on Facebook.